Breakthrough Gene-Editing Treatment for HIV Infection Led by Drs. Kamel Khalili, Tricia Burdo, and Their Teams at the Lewis Katz School of Medicine Receives Fast Track Designation from FDA

EBT-101, a one-of-a-kind gene-editing treatment for HIV infection that is the product of a collaborative effort between researchers at the Lewis Katz School of Medicine at Temple University and Excision BioTherapeutics, Inc., has received “fast track” designation from the U.S. Food and Drug Administration (FDA). The EBT-101 Phase 1/2 clinical trial was made possible by research led by Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Microbiology, Immunology, and Inflammation; and Tricia H. Burdo, PhD, Professor and Vice Chair in the Department of Microbiology, Immunology, and Inflammation at the Katz School of Medicine. The Philadelphia Business Journal highlighted the news.